Latest News and Press Releases

SOLUTION clinical study of Sollpura™ expanded to Europe, Israel and Canada in addition to ongoing US enrollmentCraig Thompson named as President and Chief Operating OfficerAppointment of Dr....

HAYWARD, Calif., April 27, 2016 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) today announced the appointment of Brent Furse to its Board of Directors. Mr. Furse has over...

SOLUTION clinical study of oral Sollpura™ enrollment to begin soon in EuropeData from BRIGHT-SC study in IgA nephropathy planned for Q2 2016Addition of Craig Thompson as President and Chief...

HAYWARD, Calif., March 07, 2016 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) today announced the appointment of James Pennington, M.D. as interim Chief Medical Officer following...

HAYWARD, Calif., Jan. 05, 2016 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc.  (Nasdaq:ANTH) today announced the appointment of Craig Thompson as President and Chief Operating...

Closed $29 million public offering in July including full exercise of underwriters’ option to purchase additional sharesCompleted capsule manufacturing in support of the SOLUTION clinical...

HAYWARD, Calif., Oct. 28, 2015 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc. (Nasdaq:ANTH) today announced the Company’s attendance at the following healthcare conferences: November 4th,...

Study to enroll approximately 130 patients with exocrine pancreatic insufficiency More than 50 clinical sites around the United States and Europe are expected to participate Anthera to...

Anthera will regain all worldwide rights for blisibimod without cost No patients were enrolled in the BRIGHT-SC study or any other clinical study in Japan Zenyaku is required to continue...

Reached enrollment target of 400 subjects in Phase 3 CHABLIS-SC1 clinical study with blisibimod Additional data on patient-reported outcomes from Phase 2b PEARL-SC blisibimod clinical study...